Latest news with #Tapse
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Anthem Biosciences lists at 27% premium; should you book profit or hold?
Anthem Biosciences IPO listing, Anthem Biosciences share price: Shares of innovation-driven and technology-focused company Anthem Biosciences made a solid D-Street debut on Monday, July 21, following the completion of its initial public offering (IPO). The company's shares listed at ₹723.10 per share on the BSE, reflecting a premium of ₹153.10 or 26.86 per cent over the issue price of ₹570 per share. On the National Stock Exchange (NSE), Anthem Biosciences shares listed at a mildly lower premium of ₹153.05 or 26.85 per cent at ₹723.05 per share over the issue price. Anthem Biosciences IPO listing came below the grey market estimate. Ahead of their debut on the bourses, the unlisted shares of Anthem Biosciences were exchanging hands at around ₹749 per share, reflecting a grey market premium (GMP) of ₹179 per share or nearly 31.40 per cent over the issue price of ₹570 per share, showed the sources that track unofficial market activities. Should you book profit or hold? The listing of the company's shares, Prashanth Tapse, senior VP (research), Mehta Equities, said was broadly in line with expectations. While post-listing valuations may appear premium, Tapse believes these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility. "The ability to consistently deliver earnings growth, in line with street expectations, further supports its valuation," said Tapse, and recommended investors to 'hold' Anthem Biosciences for a long-term perspective. "For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, justifying the listing. Short term, we foresee ₹900 as a target, while long-term investors can hold it for ₹1,000 and above. Non-allottees should wait for some volatility to settle in price, and in any case, if the stock is available around ₹650–680, it can be considered a good range to accumulate with a long-term vision," said Tapse. Shivani Nyati, head of wealth at Swastika Investmart, on the other hand, recommended investors to secure partial profits. "The company is one of the leading global players in the CRDMO segment and enjoys a niche position, leading the pack of players. The company has shown steady growth in its top line during the reported periods," said Nyati. She further recommended the investors to retain the remaining stake with a stop-loss set at ₹650. Anthem Biosciences IPO details Anthem Biosciences IPO comprised entirely an offer-for-sale (OFS) with promoters and shareholders divesting up to 59.6 million equity shares estimated to be worth ₹3,395 crore. The public issue was offered at a price band of ₹540–570 with a lot size of 26 shares, and was open for subscription from July 14, 2025, till July 16, 2025. Anthem Biosciences received strong demand from investors for its public issue as it got oversubscribed by 63.86 times. The demand was led by the qualified institutional buyers (QIBs), who bid for 182.65 times the category reserved for them, showed the NSE data. Anthem Biosciences, as outlined in its red herring prospectus (RHP), will not use any proceeds from the public issue, and it will be given to the promoters and shareholders selling their stakes through the OFS. About Anthem Biosciences Incorporated in 2006, Anthem Biosciences is a contract research, development, and manufacturing organisation (CRDMO) serving global customers. The company manufactures specialised fermentation-based APIs, including probiotics and enzymes. Anthem Biosciences has a diverse customer base, including biotech firms and large pharmaceutical companies, spanning over 44 countries. As of September 2024, the company had 196 projects and over 425 customers in its CRDMO business. The company holds one patent in India and seven overseas, with 24 pending global patent applications.
Mint
2 days ago
- Business
- Mint
Anthem Biosciences share price gains after strong listing. Should you buy, sell or hold the stock?
Anthem Biosciences share price made a stellar debut in the Indian stock market today, July 21, after its initial public offering (IPO) received a strong demand. Anthem Biosciences shares listed at ₹ 723.05 apiece on the NSE, a premium of 26.85% over the issue price of ₹ 570 per share. On BSE, Anthem Biosciences share price opened at ₹ 723.10 apiece, higher by 26.86% from the IPO price. Anthem Biosciences is a manufacturer of specialised fermentation-based APIs, and its IPO was heavily oversubscribed. Anthem Biosciences IPO listing date was today, July 21, 2025. Anthem Biosciences IPO listing was in line with the Street estimates, as indicated by the grey market premium (GMP). Anthem Biosciences IPO GMP today, and analysts had signalled a strong debut of shares. Here's what investors should do after Anthem Biosciences' share listing today. Mahesh M. Ojha, AVP - Research & Business Development at Hensex Securities, advises short-term investors who were allotted shares to consider booking partial profits as he believes over 25% gain at listing is substantial, and booking gains allows for risk management. 'Long-term investors should focus on the company's growth roadmap. Anthem has strong fundamentals, but future performance will depend on margin sustainability, innovation pipeline, and global client growth. For investors who missed the IPO, it would be wise to wait for a few trading sessions. Once the stock stabilises, it may offer a better entry point based on earnings visibility and peer comparison,' Ojha said. According to Prashanth Tapse, Sr. VP Research at Mehta Equities, Anthem Biosciences made a healthy debut, broadly in line with expectations, reflecting strong investor appetite. 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility. The ability to consistently deliver earnings growth, in line with street expectations, further supports its valuation,' Tapse said. Hence, looking at its all financial as well as sectorial, he recommends investors to 'Hold' Anthem Biosciences shares for a long-term perspective. 'For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, justifying the listing. In the short term, we foresee ₹ 900 as the target for Anthem shares, while long-term investors can hold it for ₹ 1,000 and above. Non-allottees can wait for some volatility to settle in price, and in any case, if the stock is available around ₹ 650-680, it can be considered a good range to accumulate with a long-term vision,' Tapse said. Shivani Nyati, Head of Wealth at Swastika Investmart, recommends investors to secure partial profits and retain the remainder with a stop-loss set at ₹ 650. Anthem Biosciences IPO was open from July 14 to July 16. The IPO was subscribed 63.86 times in total, as per the NSE subscription data. The retail portion was booked 5.64 times, while the Non-Institutional Investors (NII) segment was subscribed 42.36 times. The Qualified Institutional Buyers (QIBs) category received 182.65 times subscription. At 12:25 PM, Anthem Biosciences' share price was trading at ₹ 728.90 apiece on the BSE, up by 0.80% from its listing price, and up 27.88% from its issue price.
Mint
2 days ago
- Business
- Mint
Anthem Biosciences share price gains after strong listing. Should you buy, sell of hold the stock?
Anthem Biosciences share price made a stellar debut in the Indian stock market today after its initial public offering (IPO) received strong demand. Anthem Biosciences shares were listed at ₹ 723.05 apiece on the NSE, a premium of 26.85% to the issue price of ₹ 570 per share. On BSE, Anthem Biosciences share price opened at ₹ 723.10 apiece, higher by 26.86% from the IPO price. Anthem Biosciences is a manufacturer of specialized fermentation-based APIs and its IPO was heavily oversubscribed. Anthem Biosciences IPO listing date was today, 21 July 2025. Anthem Biosciences IPO listing was in line with the Street estimates as indicated by the grey market premium (GMP). Anthem Biosciences IPO GMP today ahead of the listing and analysts had signalled a strong debut of shares. Here's what investors should do after Anthem Biosciences share listing today. Mahesh M. Ojha, AVP - Research & Business Development at Hensex Securities Pvt. Ltd. advises short-term investors who were allotted shares to consider booking partial profits as he believes over 25% gain at listing is substantial, and booking gains allows for risk management. 'Long-term investors should focus on the company's growth roadmap. Anthem has strong fundamentals, but future performance will depend on margin sustainability, innovation pipeline, and global client growth. For investors who missed the IPO, it would be wise to wait for a few trading sessions. Once the stock stabilizes, it may offer a better entry point based on earnings visibility and peer comparison,' Ojha said. According to Prashanth Tapse, Sr Vp Research & Research Analyst at Mehta Equities Ltd, Anthem Biosciences made a healthy debut, broadly in line with expectations, reflecting strong investor appetite. 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility. The ability to consistently deliver earnings growth, in line with street expectations, further supports its valuation,' Tapse said. Hence, looking at its all financial as well as sectorial, he recommends investors to 'Hold' Anthem Biosciences shares for long-term perspective. 'For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, justifying the listing. Short term we foresee ₹ 900 as target while long term investors can hold it for ₹ 1,000 and above. Non allottees wait for some volatility to settle in price and in any case if the stock is available around ₹ 650-680, can be considered a good range to accumulate with long term vision,' Tapse said. Shivani Nyati, Head of Wealth at Swastika Investmart Ltd. recommends investors to secure partial profits and retain the remainder with a stop-loss set at ₹ 650. Anthem Biosciences IPO was open from July 14 to July 16. The IPO was subscribed 63.86 times in total, as per the NSE subscription data. The retail portion was booked 5.64 times, while the Non Institutional Investors (NII) segment was subscribed 42.36 times. The Qualified Institutional Buyers (QIBs) category received 182.65 times subscription. At 12:25 PM, Anthem Biosciences share price was trading at ₹ 728.90 apiece on the BSE, up by 0.80% from its listing price, and up 27.88% from its issue price. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
5 days ago
- Business
- Mint
Closing bell! Enviro Infra to Tata Motors- Prashanth Tapse of Mehta Equities suggests stocks to buy in the short term
Stock market today: The benchmark indices Sensex and Nifty experienced a significant decline on Friday due to foreign fund withdrawals and a lackluster beginning to the quarterly earnings season, which negatively affected investors' mood. Analysts noted that the sentiment surrounding banking stocks is particularly cautious following Axis Bank's recent financial results, which did not meet market expectations. The 30-share Sensex plummeted by 651.11 points or 0.79% to reach 81,608.13 during the trading day. Similarly, the 50-share Nifty 50 fell by 192.8 points or 0.76% to settle at 24,918.65. Prashanth Tapse from Mehta Equities suggests that if the Nifty 50 remains below 25,000, it may swiftly drop to 24,800 or even lower, making risk management crucial in the current circumstances. Tapse recommends these three stocks to buy in the near-term. Here's what he says about the overall market. Nifty 50 has fallen below the important 25,000 mark, showing that the market is turning more negative. This break suggests that the index may move down further, with the next support at 24,800. The failure to stay above 25,000 means sellers are still in control, possibly due to both global and local worries. Technical signals like RSI show weakness. Traders with short positions should keep a strict stop-loss at 25,100. If Nifty 50 stays under 25,000, it could quickly fall to 24,800 or lower, so managing risk is very important in these conditions. Bank Nifty has slipped below its key support of 56,600, making banking stocks more vulnerable. The index could drop further to 56,000 or even 55,500, with 55,000 as a major support if selling continues. Technical indicators show a negative trend, and many private and PSU banks are under pressure. The short-term view is weak, so traders should keep a stop-loss at 57,000 on their shorts. Unless Bank Nifty moves back above 56,600, more declines are possible. It's best to wait for clear signs of recovery before buying aggressively. Prashanth Tapse recommends buying these three stocks in the short term - Enviro Infra, Tata Motors, and Astral. Buy at: ₹ 299 | Stop Loss: ₹ 294 | Target: ₹ 325, ₹ 330 Enviro Infra share price is starting to recover after a recent fall. The stock is close to strong support at ₹ 294, giving a good entry point with low risk. Technical indicators point to a possible move up towards ₹ 325 and ₹ 330. Traders can consider buying at the current price, but must keep a stop-loss at ₹ 294. Rising volumes will add confidence to the bullish view. If the stock closes below ₹ 294, the positive outlook will not hold, so following the stop-loss is important. Buy at: ₹ 684 | Stop Loss: ₹ 650 | Target: ₹ 750 Tata Motors share price looks attractive after falling back to ₹ 684. The stock is holding above key averages and may bounce back to ₹ 750. Technical charts, including RSI, show signs of a possible recovery. Traders should set a stop-loss at ₹ 650 to control risk. If the price goes above ₹ 700 and stays there, it will be a stronger buy signal. Weakness can be used to buy more, but if it falls below ₹ 650, positions should be exited. Buy at: ₹ 1,507 | Stop Loss: ₹ 1,450 | Target: ₹ 1,650, ₹ 1,700 Astral share price is moving sideways near support at ₹ 1,507 and could bounce back from here. The overall trend is still positive, with targets at ₹ 1,650 and ₹ 1,700 if buying picks up. Short-term technical indicators are showing some stability. Buy at current levels with a stop-loss at ₹ 1,450 to protect downside. If the price breaks above ₹ 1,530, it will confirm the bullish view. As long as the stop-loss is respected, the chances for higher levels remain good. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
6 days ago
- Business
- Mint
Trump's tariffs: What market trading strategy should investors adopt amid uncertainty?
Stock market today: Indian equity benchmark indices - Sensex and Nifty - began Thursday's session on a flat note, following subdued sentiment in Asian markets amid investor unease over the uncertain future of US Federal Reserve Chair Jerome Powell. As of 9:19 am, the BSE Sensex had gained 33 points, or 0.04%, reaching 82,668, while the Nifty50 inched up by 8 points, or 0.03%, to 25,230. Markets continue to remain in a cautious trading zone, awaiting concrete Q1 earnings data to gauge real economic momentum, while uncertainty around Trump's tariff-related statements continues to fuel volatility. ' Any earnings disappointment could increase downside pressure. In such an environment, traders should prioritize disciplined execution, employ strict stop-losses to avoid large drawdowns, and diversify positions across sectors or asset classes to reduce specific risks,' said Prashanth Tapse, Sr VP Research Analyst at Mehta Equities Ltd. According to Tapse, the undertone in Nifty remains strong, with every dip being bought into. ' A decisive close above 25,350 will likely confirm continued strength and open the path for further upside. However, if Nifty closes below 25,080, there is a risk of testing the 50-day DMA near 24,950. A sustained trade below this level could lead to deeper corrections,' Tapse said. Meanwhile, Shrikant Chouhan, Head of Research - Equity, Kotak Securities, believes that market's volatility within a narrow range is a healthy sign, hinting at a corrective phase of the recent uptrend from 24,500 to 25,650. ' With value buying emerging, the focus should remain on quality stock selection while maintaining active participation at every level. Technically, a close above 25,500 may open the gates to 26,000, while a break below 25,000 could dampen near-term sentiment,' Chouhan said. Prashanth Tapse of Mehta Equities recommend short-term traders to find opportunities in volatility by capitalizing on small price moves and booking profits or losses swiftly. Meanwhile, long-term investors should view market dips as opportunities to accumulate high-quality companies with strong balance sheets and consistent earnings visibility. On the other hand, Anuj Gupta, Director, Ya Wealth Research & Advisory, advises investors should trade with strick stoploss levels in the volatile market. ' Generally in the volatile market, prices goes elsewhere, trend not clear. So generally in that case the chances of stoploss triggered very can go with less quantity positions. Firstly they should calculate important key levels to enter and exit. Timing of the market is always very important. One should keep eyes on sectoral or individual stock to trade based on its fundamental values. They can also us hedging strategy by using option trading to protect the position and limit the losses,' Gupta said. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
